A collaborative translational study that included data from six neoadjuvant GBG trials (GeparDuo, GeparTrio, GeparQuattro, GeparQuinto, GeparSixto and GeparSepto) and investigated the role of tumour-infiltrating lymphocytes (TILs) as a prognostic factor in different subtypes of breast cancer after neoadjuvant therapy has been published in the The Lancet Oncology.
The analysis of this large clinical cohort of patients with different breast cancer subtype treated with neoadjuvant chemotherapy showed that an increased TIL concentration predicted treatment response in all molecular subtypes and was associated with longer survival in TNBC and HER2-positive breast cancer compared to luminal-HER2-negative tumours. Thus, these results support the hypothesis that breast cancer is immunogenic and immune-modulating therapies can be applied.
Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt WD, Blohmer JU, Karn T, Pfitzner BM, Kümmel S, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching PA, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Loibl S.
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Lancet Oncol. 2018;19:40-50.
Link in PubMed